Pilar Mendoza Daroca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8597003/publications.pdf

Version: 2024-02-01

759055 1125617 5,033 13 12 13 citations h-index g-index papers 19 19 19 10935 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research. Current Opinion in HIV and AIDS, 2021, 16, 25-35.	1.5	7
2	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates. Journal of Virology, 2021, 95, .	1.5	18
3	Evolution of antibody immunity to SARS-CoV-2. Nature, 2021, 591, 639-644.	13.7	1,355
4	Persistent cellular immunity to SARS-CoV-2 infection. Journal of Experimental Medicine, 2021, 218, .	4.2	115
5	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature, 2021, 600, 517-522.	13.7	239
6	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 2020, 584, 437-442.	13.7	1,742
7	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. Journal of Experimental Medicine, 2020, 217, .	4.2	503
8	Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir. Journal of Experimental Medicine, 2020, 217, .	4.2	75
9	Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nature Medicine, 2020, 26, 222-227.	15.2	108
10	Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir. Journal of Experimental Medicine, 2019, 216, 2253-2264.	4.2	92
11	Relationship between intact HIV-1 proviruses in circulating CD4 ⁺ T cells and rebound viruses emerging during treatment interruption. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11341-E11348.	3.3	65
12	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature, 2018, 561, 479-484.	13.7	392
13	Relationship between latent and rebound viruses in a clinical trial of anti–HIV-1 antibody 3BNC117. Journal of Experimental Medicine, 2018, 215, 2311-2324.	4.2	84